Know Cancer

forgot password

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)

Open (Enrolling)
Myeloid Hematological Malignancies

Thank you

Trial Information

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)

The following will be given as the conditioning regimen for the transplant:

BUSULFAN: Busulfan (intravenous BUSULFEX) dosing will be as follows: patients <12 kg: 1.1
mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6
hours for 16 doses. Administration and pharmacokinetic monitoring will be performed as per
standard practice. Anticonvulsants will be given in accordance with standard Blood and
Marrow Transplant Program recommendations.

CYCLOPHOSPHAMIDE: Cyclophosphamide (50 mg/kg/dose) will be given IV on day -5, - 4, -3, and
-2 over 2 hours. The total dose to be given over 4 days is 200 mg/kg. Mesna will be given in
accordance with standard Blood and Marrow Transplant.

FLUDARABINE: Fludarabine 40 mg/m2 will be given I.V. daily over 1 hour for 3 days.
Preparation, administration and monitoring will be according to standard practice procedure.


- CSA will begin on day -3. For children <40 kg, the initial dose will be 2.5 mg/kg IV
over 2 hours every 12 hours. Dose adjustments will be made to maintain levels above
200ng/ml. Levels will be done on day 0 and then as clinical indicated. CSA will be
tapered per institutional SOP. Once the patient can tolerate oral medications and has
a normal gastrointestinal transit time, CSA will be converted to an oral form.

- MMF will begin on day 0 at a dose of 15 mg/Kg IV or orally tid and will be discontinued
on day +45 unless GVHD is present.

CNS disease: Patients with CNS relapse or primary CNS disease that is symptomatic or
associated to radiological changes will receive additional irradiation to the craniospinal


- Supportive care will be provided as per standard practice of the Blood and Marrow Stem
Cell Transplant program at the Texas Children's Hospital, including all prophylactic
and therapeutic clinical care issues. These practices may be modified if necessary for
any individual patient in order to provide optimum care for that particular patient.

- IVIG: Intravenous immunoglobulin (500mg/kg per dose) will be given monthly until
discontinuation of GVHD therapy and documentation of antibody production.

- CB-CTLs: Patients enrolled in this protocol may also be eligible for infusion of
CB-derived multivirus-specific CTL to provide virus-specific immune reconstitution and
treatment of viral infections after CBT.


Screening Procedures; Pre-HCT:

- Physical examination

- Pregnancy Test

- Complete blood count and chemistries

- Electrocardiogram

- Viral tests

- Bone marrow aspirate and biopsy/Lumbar puncture

- Renal Function (GFR)

- Lumbar puncture will be performed

- Pulmonary Function Test


- Physical examination

- Complete blood count and chemistries

- Peripheral blood for STRs or FISH analysis for molecular diagnostics

- Lymphocyte phenotype testing and lymphoproliferative responses

- Bone marrow aspirate and biopsy for assessment of leukemia status and UCB engraftment

- Lumbar puncture

- immunoglobulins


- Physical examination

- Complete blood count and chemistries

- Peripheral blood with assessment of engraftment by STRs or FISH analysis and enzyme

- Echocardiograph with LVEF

- Bone marrow aspirate and biopsy assessment of leukemia status and UCB engraftment

- Lymphocyte phenotype testing (CD3, CD4, CD8, CD14, CD19 and CD56) and
lymphoproliferative responses Immunoglobulins


Patients will be seen in the hospital everyday until discharge. After discharge from the
hospital, the patient will be following on the BMT clinics on a regular basis as recommended
by the primary physician.

Inclusion Criteria:

- Patients with a myeloid hematologic malignancy (acute myelogenous leukemia, secondary
myelogenous leukemia or myelodysplastic syndrome) unlikely to be cure by standard
chemotherapy. This includes patients who have relapsed after standard chemotherapy
treatments and patients in first remission with unfavorable prognostics features.

- Related or Unrelated Umbilical Cord Blood Unit with 0-1 antigen mismatch at HLA-A and
B (at low resolution) and DRB1 (at high resolution) with a total nucleated cell dose
of ≥ 4x10^7/kg

- Lansky/Karnofsky scores at least 60

- Written informed consent and/or signed assent line from patient, parent or guardian.

- Negative Pregnancy Test, if applicable

Exclusion Criteria:

- Patients with uncontrolled infections. For bacterial infections, patients must be
receiving definitive therapy and have no signs of progressing infection for 72 hours
prior to enrollment. For fungal infections patients must be receiving definitive
systemic antifungal therapy and have no signs of progressing infection for 1 week
prior to enrollment. Progressing infection is defined as hemodynamic instability
attributable to sepsis or new symptoms, worsening physical signs or radiographic
findings attributable to infection. Persisting fever without other signs or symptoms
will not be interpreted as progressing infection.

- Severe renal disease (Creatinine > x 3 normal for age)

- Severe hepatic disease (direct bilirubin > 3 mg/dl or SGOT > 500)

- Patient has DLCO < 50% predicted or FEV1 < 50% of predicted, if applicable

- Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence
of significant cardiac dysfunction by echocardiogram (shortening fraction <20%).

- HIV Positive

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival at 1 year after UCB transplant in pediatric patients

Outcome Description:

To determine the overall survival rate at 1 year after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies.

Outcome Time Frame:

1 year

Safety Issue:


Principal Investigator

Caridad A Martinez, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Baylor College of Medicine


United States: Institutional Review Board

Study ID:




Start Date:

November 2010

Completion Date:

November 2020

Related Keywords:

  • Myeloid Hematological Malignancies
  • UCB
  • Umbilical Cord Blood
  • Transplant
  • Umbilical Cord Blood Transplant
  • Cord Blood Stem Cell Transplantation
  • Pediatric
  • Myeloid Hematological Malignancies
  • Busulfan
  • Cytoxan
  • Cyclophosphamide
  • Fludarabine
  • Neoplasms
  • Hematologic Neoplasms



Texas Children's HospitalHouston, Texas